Pericapsular Exparel for Pain Relief in Bunionectomy and Related Procedures

Overview

Exparel is an FDA-approved local anesthetic (bupivacaine), in a long-release formulation. In this study the investigators plan to determine the ability of Exparel to control post-operative pain in common first metatarsophalangeal (MTP) joint procedures (bunion surgery, 1st MTP fusion, and cheilectomy).

Full Title of Study: “Exparel Pericapsular Injection: A Prospective Evaluation of Postoperative Pain in Bunion Surgery, First Metatarsophalangeal Joint Fusion, and Cheilectomy”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Supportive Care
    • Masking: Single (Participant)
  • Study Primary Completion Date: January 2016

Detailed Description

The investigators propose a prospective, randomized, single-blinded study of patients who are electing to undergo an outpatient first metatarsophalangeal (MTP) joint procedure (bunionectomy, 1st MTP fusion, or cheilectomy). As a standard, patients undergoing these procedures are given regional anesthesia (adductor canal block plus popliteal block). Patients are then given prescriptions for oral opioids to manage post-operative pain. The purpose of this study is to determine whether a single intrapopliteal administration of Exparel, in conjunction with the standard of care regional block, improves pain relief and therefore decreases use of post-operative opioids.

Interventions

  • Drug: 0.5% ropivacaine
    • Adductor block: 10 mL of 0.5% ropivacaine; popliteal block: 30 mL of 0.5% ropivacaine
  • Drug: Exparel
    • 106 mg (8 mL, equivalent to 120 mg bupivacaine HCl)

Arms, Groups and Cohorts

  • Active Comparator: Regional Block
    • Group A patients will receive only a pre-operative adductor canal block with 10 mL 0.5% ropivacaine plus a popliteal block with 30 mL 0.5% ropivacaine (total block 40 mL/200 mg).
  • Experimental: Regional Block Plus Exparel
    • Group B patients will receive the standard of care pre-operative adductor and popliteal block as described (40 mL/200 mg of 0.5% ropivacaine) in addition to a postoperative pericapsular injection of Exparel using 106 mg (8 mL, equivalent to 120 mg bupivacaine HCl), per the same total dose as provided in manufacturer recommendations.

Clinical Trial Outcome Measures

Primary Measures

  • Opioid Use as Measured by Questionnaire
    • Time Frame: Daily through the third day (72 hours) post-surgery
    • Compare time to first opioid use over 72 hours between groups
  • Total Opioid Use as Measured by Questionnaire
    • Time Frame: Daily through the third day (72 hours) post-surgery
    • Compare total opioid use (reported as total morphine equivalents) over 72 hours between groups.

Secondary Measures

  • Pain Relief Measured by Defense and Veterans Pain Scale
    • Time Frame: Through 72 hours post-surgery (0, 6, 12, 24, 36, 48, 60, and 72 hours post-surgery)
    • Evaluate patient-reported pain scores (scale of 0 (no pain) – 10 (worst pain)) at 0, 6, 12, 24, 36, 48, 60, and 72 hours following surgery

Participating in This Clinical Trial

Inclusion Criteria

  • Age ≥ 18 – Undergoing distal or midshaft osteotomy for bunion correction, 1st MTP Fusion, or cheilectomy Exclusion Criteria:

  • Age less than 18 – Unable to read/write English – Dementia, history of dementia, or other significant mental impairment that would, in the opinion of the investigator, impede patient self-reporting – Weight <70 kg – Allergy to local anesthetics – History of long-acting opioid use or opioid tolerance (any patient receiving at least 30 mg of oxycodone or equivalent per day (e.g., 6 tabs of Percocet 5/325 mg) regularly for approximately 7 days or more OR who require increased analgesic doses for a period long enough to develop tolerance to the effects of the opioid including analgesia and sedation) – Any history of opioid misuse, illicit or prescription – Prior MTP joint correction on the surgical limb – Midfoot and hindfoot procedures performed concurrently, on the same day – Pregnant or breastfeeding

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • OhioHealth
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Christopher Hyer, DPM, Principal Investigator, OhioHealth

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.